Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

RSS icon

NYC hospitals dragging feet on price transparency

If the hospitals of America’s most populous city are any sort of bellwether, CMS is going to have its hands full trying to enforce compliance with the Trump Administration’s executive order on price transparency.

Mandating flu shot availability for healthcare workers saves patient lives

Hospitals required by state laws to offer healthcare workers flu shots can expect significantly reduced flu and pneumonia mortality compared with hospitals in states forgoing such mandates.

Hospital price transparency closing in

Is your organization ready to meet the new federal requirements on hospital price transparency? The policy is set to go live on New Year’s Day. 

Medicaid solidifies value-based drug payments

The revised system gives states greater leeway than they’ve had to cut value-based purchasing deals with pharma companies on innovative but expensive drugs.

EU trying to anticipate, head off threats AI may pose to human rights

Various scenarios within medical diagnostics are among the AI use cases that an official European watchdog has flagged as a potential source of hazards to fundamental human rights.

3 industry orgs suing HHS, FDA over Canadian drug imports

The Pharmaceutical Research and Manufacturers of America (PhRMA) is combining forces with two other groups to challenge the FDA final rule allowing broad, state-by-state importation of drugs from Canada.

Thumbnail

4 forces favoring, 5 working against Biden’s wish to lower Medicare eligibility age

President-elect Joe Biden wants to drop Medicare’s eligibility age to 60. If he succeeds, the move might bring in well more than 20 million new enrollees. What are the odds he’ll plant that piece of a potentially sweeping healthcare agenda?  

Thumbnail

3 areas newly ripe for employer-driven change in healthcare policy

A healthcare research firm specializing in purchasing has considered the post-election landscape from the vantage point of large employers offering health benefits to their workers.

Displaying 705 - 712 of 2773

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup